Physician profile
Benjamin E Brewer
NPI 1184618258
$13,195.71
in general payments reported to CMS, 2019-2025
36 companies · $1,670 in 2025
The $1,670 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $596 · 2021: $1,040 · 2022: $2,229 · 2023: $4,686 · 2024: $2,487 · 2025: $1,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,846 · Food and Beverage: $3,988 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,845.96 |
| Food and Beverage | $3,988.44 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,046.54 | 2021-2025 | Botox, Vraylar, Viberzi |
| Allergan, INC. | $2,775.49 | 2019-2023 | |
| Novo Nordisk INC | $688.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $389.05 | 2020-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $380.76 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $304.90 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Pfizer INC. | $263.01 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $232.52 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $216.92 | 2020-2025 | |
| Amgen INC. | $198.53 | 2021-2024 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.34 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $167.79 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $147.21 | 2023-2025 | Breztri, Airsupra, Pulmicort Respules |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.30 | 2021-2024 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $100.43 | 2021-2023 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.